Challenges of Health Technology Assessment in Pluralistic Healthcare Systems: An ISPOR Council Report.

health insurance health technology assessment healthcare systems pluralism

Journal

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
ISSN: 1524-4733
Titre abrégé: Value Health
Pays: United States
ID NLM: 100883818

Informations de publication

Date de publication:
08 2022
Historique:
received: 02 06 2021
revised: 01 02 2022
accepted: 10 02 2022
entrez: 5 8 2022
pubmed: 6 8 2022
medline: 10 8 2022
Statut: ppublish

Résumé

Health technology assessment (HTA) has been growing in use over the past 40 years, especially in its impact on decisions regarding the reimbursement, adoption, and use of new drugs, devices, and procedures. In countries or jurisdictions with "pluralistic" healthcare systems, there are multiple payers or sectors, each of which could potentially benefit from HTA. Nevertheless, a single HTA, conducted centrally, may not meet the needs of these different actors, who may have different budgets, current standards of care, populations to serve, or decision-making processes. This article reports on the research conducted by an ISPOR Health Technology Assessment Council Working Group established to examine the specific challenges of conducting and using HTA in countries with pluralistic healthcare systems. The Group used its own knowledge and expertise, supplemented by a narrative literature review and survey of US payers, to identify existing challenges and any initiatives taken to address them. We recommend that countries with pluralistic healthcare systems establish a national focus for HTA, develop a uniform set of HTA methods guidelines, ensure that HTAs are produced in a timely fashion, facilitate the use of HTA in the local setting, and develop a framework to encourage transparency in HTA. These efforts can be enhanced by the development of good practice guidance from ISPOR or similar groups and increased training to facilitate local use of HTA.

Identifiants

pubmed: 35931428
pii: S1098-3015(22)00108-5
doi: 10.1016/j.jval.2022.02.006
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1257-1267

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2022. Published by Elsevier Inc.

Auteurs

Michael F Drummond (MF)

Centre for Health Economics, University of York, York, England, UK. Electronic address: mike.drummond@york.ac.uk.

Federico Augustovski (F)

Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina.

Devarshi Bhattacharyya (D)

Kalam Institute of Health Technology, Andhra Pradesh, India.

Jonathan Campbell (J)

Institute for Clinical and Economic Review, Boston, MA, USA.

Nathorn Chaiyakanapruk (N)

University of Utah, Salt Lake City, UT, USA; Monash University, Selangor, Malaysia; IDEAS Center, Veterans Affairs Salt Lake City Healthcare System, Salt Lake City, UT, USA.

Yingyao Chen (Y)

Fudan University, Shanghai, China.

Rosa Maria Galindo-Suarez (RM)

Ministry of Health, Mexico.

John Guerino (J)

COEUS Consulting Group, Devon, PA, USA.

Aurelio Mejía (A)

Ministry of Trade, Industry and Tourism, Colombia.

Michelle Mujoomdar (M)

Canadian Agency for Drugs and Technologies in Health, Ottawa, Ontario, Canada.

Daniel Ollendorf (D)

Tufts Medical Center, Boston, MA, USA.

Naoko Ronquest (N)

RTI Health Solutions, Ann Arbor, MI, USA.

Aleksandra Torbica (A)

Bocconi University, Milano, Italy.

Emily Tsiao (E)

Premera Blue Cross, Mountlake Terrace, WA, USA.

John Watkins (J)

Premera Blue Cross, Mountlake Terrace, WA, USA.

Kai Yeung (K)

Kaiser Permanente Washington Health Research Centre, Seattle, WA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH